Year All20242023202220212020201920182017201620152014 Sep 26, 2023 Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Sep 25, 2023 Soleno Therapeutics to Present at the Cantor Global Healthcare Conference Aug 16, 2023 Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors Aug 08, 2023 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results May 09, 2023 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results May 03, 2023 Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Mar 28, 2023 Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days Mar 21, 2023 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results Jan 26, 2023 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome Dec 19, 2022 Soleno Therapeutics Announces Financing Commitment for up to $60 Million
Sep 26, 2023 Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Aug 16, 2023 Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
Aug 08, 2023 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
May 09, 2023 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 03, 2023 Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Mar 28, 2023 Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
Mar 21, 2023 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Jan 26, 2023 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome